Get the Stockscreener App
5.95
15.31%
0.79
After Hours:
5.95
Agenus Inc stock is traded at $5.95, with a volume of 2.50M.
It is up +15.31% in the last 24 hours and up +100.34% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$5.16
Open:
$5.19
24h Volume:
2.50M
Relative Volume:
2.67
Market Cap:
$163.15M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0865
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
+73.47%
1M Performance:
+100.34%
6M Performance:
+66.20%
1Y Performance:
-64.07%
1-Day Range:
$5.18
$6.35
1-Week Range:
$3.4582
$6.35
52-Week Range:
$1.38
$18.74
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
5.95 | 87.73M | 160.43M | -227.64M | -170.79M | -68.77 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues
Zydus enters global biologics CDMO market with $75m facility acquisitions - BioProcess International
Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN
Agenus (NASDAQ:AGEN) Upgraded to “Buy” at HC Wainwright - Defense World
Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird - Defense World
Zydus Lifesciences to acquire India, Sri Lanka rights for Agenus cancer immunotherapy BOT/BAL - Medical Dialogues
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US - 뉴스와이어
Agenus Announces Strategic Collaboration with Zydus - TipRanks
Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN
Agenus IncSigns Partnership Agreements With Zydus Lifesciences - marketscreener.com
Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangAgenus (NASDAQ:AGEN) - Benzinga
Agenus Shares Rise After Upgrade From HC Wainwright - marketscreener.com
H.C. Wainwright upgrades Agenus stock on strategic collaboration - Investing.com Australia
H.C. Wainwright upgrades Agenus stock on strategic collaboration By Investing.com - Investing.com South Africa
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade - Yahoo Finance
Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Mai - GuruFocus
Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Maintained | AGEN Stock News - GuruFocus
HC Wainwright & Co. Upgrades Agenus (AGEN) - Nasdaq
Agenus (AGEN) Upgraded to 'Buy' by HC Wainwright & Co. | AGEN Stock News - GuruFocus
Agenus (AGEN) Stock Price Target Increased by Baird | AGEN Stock News - GuruFocus
Agenus and Zydus sign agreements for botensilimab and balstilimab - Yahoo Finance
Zydus gets rights for next gen I-O platforms from Agenus - The Pharma Letter
HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target - marketscreener.com
Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | A - GuruFocus
Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | AGEN Stock News - GuruFocus
Zydus, Agenus team up for next-gen cancer immunotherapies - Healthcare Radius
Jane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business - Indian Pharma Post
Zydus Lifesciences acquires Agenus Biologics facilities in US, enters global CDMO market - Express Pharma
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies - StreetInsider
Agenus inks $141M deal with Zydus for cancer drugs, facilities By Investing.com - Investing.com South Africa
Zydus acquires Agenus biologics facilities for CDMO expansion By Investing.com - Investing.com South Africa
Zydus Lifesciences to acquire Agenus’s two biologics units for USD 125M - Medical Buyer
With plans to acquire US-based genus Inc, Zydus Lifesciences set to enter the global biologics CDMO business - financialexpress.com
Zydus Lifesciences Subsidiary Zynext to Acquire 5.9% Stake in Agenus for $16 Million - India Infoline
Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies - Equity Bulls
Zydus announces plan to acquire US manufacturing units of Agenus Inc - The Indian Express
Agenus Inc. announced that it expects to receive $15.75 million in funding from Zydus Lifesciences Limited - marketscreener.com
Zydus to acquire US biotech firm Agenus’ facilities in California - The Economic Times
Agenus Stock Is Trading Higher Tuesday: What's Going On? - Benzinga
Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million - The Hindu
Agenus to Sell US Manufacturing Facilities to Zydus Lifesciences - marketscreener.com
Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach - The Malaysian Reserve
Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy | Company Business News - Mint
Zydus bolsters global biologics play with Agenus acquisition, immuno-oncology licensing pact - Fortune India
Zydus inks pact to acquire stake in US firm to enter contract manufacturing space - theweek.in
Zydus Lifesciences to Enter the Global CDMO Business - Contract Pharma
Zydus Life To Buy Agenus US Facilities For $75 Million For Entry In Biologics CDMO - NDTV Profit
Agenus (AGEN) Rises on Zydus Partnership to Boost Cancer Therapy - GuruFocus
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
3.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):